PHAR
Cairo – Mubasher: The consolidated income statements of the Egyptian International Pharmaceutical Industries Company (EIPICO) for the first six months of fiscal year 2019 showed a marginal increase in profits when compared to the corresponding half a year earlier.
EIPICO achieved EGP 398.3 million worth of profits in the interim consolidated financials of this year, compared to EGP 388.3 million in H1-18, including minority shareholders’ rights.
Based on the consolidated financial statements for the H1-19 period, the pharmaceutical company registered sales of EGP 1.7 billion, up from EGP 1.4 billion in H1-18, according to a bourse disclosure to the Egyptian Exchange (EGX) on Thursday.
It is worth noting that on Wednesday, the company announced its initial unconsolidated financials which indicated EGP 371.2 million worth of profits in H1-19.